CClinicalTrials.gg
Sign In
RecruitingNCT02814032Updated Jul 20, 2023

Proteomics of Papillary Thyroid Carcinoma

An observational study in Papillary Thyroid Carcinoma, sponsored by The Affiliated Hospital of Inner Mongolia Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-20.

Sponsored by The Affiliated Hospital of Inner Mongolia Medical University · Observational

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
32
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Thyroid carcinoma is the common endocrine system malignant neoplasm. At present it has become the malignant neoplasm of fastest growing incidence rate. More than 85% thyroid carcinoma is papillary thyroid carcinoma. Cervical lymph node metastasis is common in papillary thyroid carcinoma patients. This study aim to reveal protein expression differences between papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis.

Read the detailed description
  1. Object: Patients aged 18-65 years; newly diagnosed papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer.
  2. Clinical information, examination data: Information is obtained from medical record abstraction.
  3. Samples: Fresh frozen thyroid tissues from each sample group(normal histology, benign disease, papillary thyroid carcinoma with cervical lymph node metastasis, papillary thyroid carcinoma without cervical lymph node metastasis ).
02

Conditions studied

  • Papillary Thyroid Carcinoma

Keywords

  • proteomic
  • cervical lymph node metastasis
03

In context

Carcinoma

6,741 studies on the registry are indexed under Carcinoma; 1,161 are open to participants now.

This study's planned enrollment of 32 is below the median of 149 across 1,175 observational studies indexed under Carcinoma.

Browse Carcinoma studies →

Lead sponsor

The Affiliated Hospital of Inner Mongolia Medical University is the lead sponsor of 9 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients aged 18-65 years; newly diagnosed papillary thyroid carcinoma with cervical lymph node metastasis and without cervical lymph node metastasis and undergone thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer.

Inclusion criteria

  • Newly diagnosed papillary thyroid carcinoma.
  • Undergo thyroidectomy according to the China thyroid association guidelines forthe Management of thyroid nodule and thyroid cancer.

Exclusion criteria

Exclusion Criteria:

  • Current substance abuse/dependence.
  • Daily tobacco and alcohol use.
  • Whole neck irradiation or surgery.
  • Prior cancer diagnosis or chemotherapy treatment.
  • Active autoimmune disorder.
  • Uncontrolled allergic condition or asthma.
  • Chronic use of oral steroid medication.
  • Hormone therapy (estrogen, progestin compounds).
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
32 participants (estimated)
Patient registry
No

Groups and cohorts

  • PTC group 1

    papillary thyroid carcinoma patients with cervical lymph node metastasis

  • PTC group 2

    papillary thyroid carcinoma patients without cervical lymph node metastasis

  • Positive control group

    benign disease

  • Negative control group

    histologically normal

06

What researchers measure

Primary outcomes

  1. differences in protein expression

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Gharib H, Papini E. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am. 2007 Sep;36(3):707-35, vi. doi: 10.1016/j.ecl.2007.04.009. PubMed 17673125 ↗
  • Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020. PubMed 26462967 ↗
  • Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW, Haugen BR. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog. 2006 Aug;45(8):613-26. doi: 10.1002/mc.20193. PubMed 16788983 ↗
  • Sofiadis A, Becker S, Hellman U, Hultin-Rosenberg L, Dinets A, Hulchiy M, Zedenius J, Wallin G, Foukakis T, Hoog A, Auer G, Lehtio J, Larsson C. Proteomic profiling of follicular and papillary thyroid tumors. Eur J Endocrinol. 2012 Apr;166(4):657-67. doi: 10.1530/EJE-11-0856. Epub 2012 Jan 24. PubMed 22275472 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 20, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02814032
Lead sponsor
The Affiliated Hospital of Inner Mongolia Medical University
Responsible party
Sponsor
First posted
Jun 27, 2016
Start date
Jun 2016
Primary completion
Dec 2023 (estimated)
Completion
Jun 2024 (estimated)
Last update
Jul 20, 2023

Study contacts

Shan Jin, PhD
Contact
jinshangood@163.com
+86-15849338280
Yun-tian Yang, PhD
Contact
yangyuntian@sina.com
+86-15849338737
Shan Jin, PhD
study director · Affiliated Hospital of Inner Mongolia Medical University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Carcinoma→

Other studies from this sponsor

The Affiliated Hospital of Inner Mongolia Medical University

Start the discussion